Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (January 2022)
50 slides from Genprex's investor presentation, Jan 3, 2022
Slide 1: Reprogramming the Course of Cancer and Diabetes
©) Genprex’ REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX January 2022
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS “Statements contained in this presentation regarding matters thatare not historical facts are “Yonward-lookingstatements" within the meaning ofthe Private Securities Ligation Reform Actof 1995, Because such statements are subjectto risks and uncertainties, actual results m
Slide 3: GNPX at a Glance
GNPX AT A GLANCE 10-DAY AVG. SHARES VOLUME | OUTSTANDING company | symeot | excHaNce | SHAREPRICE | MARKET CAP Genprex, Inc. GNPX Nasdaq $130 $62 399K 47808570 $42Million All dotaore as of December 21, 2021, except for shares outstonding which is as of November 8, 2021, and cosh which is as of Septe
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS Novel gene therapies addressing cancer and diabetes Addressing unmet medical need in large markets through the bulldoutof a robust pipeline of new drug candidates and crug combinations Leveraging a gene therapy platform: Genprex’s non-viral Oncoprex® nanoparticle delivery syste
Slide 5: Executive Summary
+ GENE THERAPY PLATFORM. EXECUTIVE SUMMARY MAJOR COMPETITIVE ADVANTAGES, DEMONSTRATED CLINICAL ACHIEVEMENT + FIRST SYSTEMIC GENE THERAPY q INITIATED ONELUNG CANCER CLINICAL USED FOR CANCER IN HUMANS / ‘ TRIAL, EXPECT TO INITIATE SECOND aa, CLINICAL TRIAL IN Q1 2022 7 HARE MARKETS AND UNMET NEED A WO
Slide 6: Research and Development Pipeline
© Genprex RESEARCH AND DEVELOPMENT PIPELINE ISCOVE cuNICAL, ‘CLINICAL ‘CLINICAL Discovery precuNicaL CLINICAL cunicaL Ghee Acclairn-1 po ng <n? oxcoon << << —— ae — 4 US onto ta ipmtin Nasdaq: GNP 6
Slide 7: Bridging Gaps in Modern Medicine
BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES ‘* REQORSA\s the first systemic gene therapy in © Gene therapy drug candidate addresses Type 1 and development for cancer. Type 2 diabetes. ‘* Planned clinical trials include combinations of ‘* May red
Slide 8: Slide 8
Slide 9: Non-Small Cell Lung Cancer
NON-SMALL CELL LUNG CANCER MARKET STATISTICS MOST L% LUNG CANCER TAGRISSO 2020 SALES NSCLC represents the majority of all lung cancers. AstraZeneca's highest grossing product. WORLDWIDE CASES KEYTRUDA 2020 SALES More than two million cases per year worldwide. Merck's highest grossing product. UNITED
Slide 10: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM The first systemic gene therapy delivery platform for cancer GENES Multiple tumor suppressor genes SYNERGIES ‘Advanced approach using combination therapy CANCERS Multiple cancers Genprex ‘Nasdag:GNPX 10
Slide 11: Oncoprex Nanoparticle Delivery System
ONCOPREX NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS Positively charged TUSC2 gene nanoparticle Cassette S) ° ° Negatively charged cancer cell Nanoparticle attaches Cancer killing genes Cell death to cancer cell integrate into cell Our nen.viral, biodegradable, po
Slide 12: Targeting Negative Surface Charges of Cancer Cells
TARGETING NEGATIVE SURFACE CHARGES OF CANCER CELLS AN INNOVATIVE MEANS TO SELECTIVELY TARGET CANCER CELLS + The activites of glucose metabolism have a profound impact on the surface of cancer cells + Elevated glycolysis in cancer cells lead toa higher secretion of lactate + Secreted lactate ions rem
Slide 13: REQORSA Targets Cancer at Its Core
REQORSA™ TARGETS CANCER AT ITS CORE DOTAP: CL-TUSC2 ~ CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS — MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Nasdag:GNPX 13
Slide 14: TUSC2 Inhibits Key Cell Signaling
TUSC2 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS - Nasdag:GNPX 14
Slide 15: REQORSA Monotherapy
REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: ee eeee 311 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=3 Highest
Slide 16: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION PHASE 2 PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS PRIOR LINES OF Si AI PATIENT EGFR STATUS RESPONSE PRIOR THERAPY SES AE Positive (exon 18+20) Complete Response ‘Chemo 3 Negative 2496 regression Target Lesion ‘Chemo /ant-PD1 2 30% regression one Target
Slide 17: REQORSA + Tarceva Swimmer Plot
EGFR status/mutation REQORSA + TARCEVA COMBINATION ‘Swimmer Plot of Best Response, with Time on Study Negatve Negative Positive (exon 18+20) 4 Negative 4 Negative 4 Negative 4 Negative 4 Negative 4 Positive (exon 21) 4 Negative 4 Negative + Positive (exon 21) 4 so + Chemotherapy ‘4 Chemotherapy+immu
Slide 18: REQORSA + Tagrisso Reduce Tumor Growth in Resistant Tumors
AACR 21: REQORSA + TAGRISSO REDUCE TUMOR GROWTH IN TAGRISSO-RESISTANT TUMORS fi seen Osimertinib+TUSC2 combination on insert -Toscs cornissen ¢ ‘Osimertinib+ TUSC2 combination on 1975 tumors in NSG mice 200 = soo: E wo = 100 5 H 8 ao: Bs : . eS) bs o- oh of of of o% of of CA RCABCI TCS RCW aOS Days
Slide 19: General Study Characteristics
GENERAL STUDY CHARACTERISTICS + REQORSA in combination with AstraZeneca's Tagrizso for NSCLC + Inerim analysisat 25 events (Le, disease progressionor 1 FDA FastTrack Designation death) Patients with advanced, EGFR mutant NSCLC whose disease progressed after Tagrisso + 15US.sices + 792 patients Phase
Slide 20: Primary Endpoint
PRIMARY ENDPOINT 1 BME. 343 dose escalation of + Dose limiting toxicity re REQORSA in combination with Tagrisso* PHASE = PRIMARY ENDPOINT SECONDARY ENDPOINTS. IG Randomized 1:1, operlabel, + Progression free survival (PES) ~ Quer esponse rate we 2atm study of REQORSA In {PFS improvement of REQORSA c
Slide 21: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER Survival on Lung Metastasis Model ‘Tusce- treated of Se. r = — usc 2 as 2ePOIECTLAS iv io 6 Es a6 cere TUSC2+ant-PD1 exhibit greater antitumor activity than TUS oe competency rcl
Slide 22: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda Strong antitumor immune responses of ant:PD1 were found against PDX tumors developed in humanized mice, Immunomadulation of Pembro + TUSC2 demonstrates rationale for
Slide 23: REQORSA May Enhance First-Line Standard of Care
AACR 21: REQORSA MAY ENHANCE FIRST-LINE STANDARD OF CARE REQORSA MAY OVERCOME RESISTANCE TO KEYTRUDA + CHEMO COMBINATION REQORSA + Keytruda + Chemo ‘+ REQORSA enhances the efficacy of chemo-immunotherapy on KL-mutant lung metastases In humanized mice. + Triple combination demonstrated strong antitum
Slide 24: REQORSA Shows Synergy with Immunotherapy + Chemotherapy
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPY + CHEMOTHERAPY A active Tells (Lung) B REQORSA + Keytruda + Chemo REQORSAtanti-PD1#chemo combination resulted in metastasis regression significantly greater than either REQORSA alone or ant-PDt#chemo. Note: Treg ond Myeloid ore Immunosuppressive RTM wet Nasca
Slide 25: Acclaim-2 General Study Characteristics
Aedain -2 GENERAL STUDY CHARACTERISTICS + REQORSA in combination with Merck & Co's Keytruda for NSCLC + Interim analysisat 50 events (Le, disease progression FDA Fast Track Designation received December 2021) or death) Patients with advanced NSCLC whose disease progressedafter reatmentwith + Phase |
Slide 26: Acclaim-2 Endpoints
Acclaim: 2 PHASE 1 COMPONENT + 343 dose escalation of REQORSA in combination with Keytruda PRIMARY ENDPOINT Dose limiting toxicity a8 Zz <8 zs ° + Randomized 2:1, openabel, 2.arm study of REQORSA in combination with Keytruda vs. docetaxel #7: ramucrumab PRIMARY ENDPOINT + Progression free survival (
Slide 27: Scaled-Up Clinical Grade Manufacturing
SCALED-UP CLINICAL GRADE MANUFACTURING MILESTONE POSITIONS COMPANY FOR SUCCESS IN LUNG CANCER THERAPEUTICS MARKET Achievement highlighted by important process improvements and significantly improved economies of scale. + Successful completion of technology transfer and scale-up of REQORSA + GMP prod
Slide 28: REQORSA in Small Cell Lung Cancer
REQORSA IN SMALL CELL LUNG CANCER EXPANDING REQORSAFOR THE ENTIRE LUNG CANCER MARKET ‘Targeting Smalll Cell Lung Cancer (in addition to NSCLO) allows Genprex to address the entire lung cancer market. ‘Small Cell Lung Cancer: + Consistently has low TUSC2 protein levels + Documented to often have dele
Slide 29: ne be lu aU <2 Oa
ne be lu aU <2 Oa
Slide 30: Diabetic Patients in Need of Advanced Treatment
DIABETIC PATIENTS IN NEED OF ADVANCED T GPX-002 MAY ELIMINATE THE RY ABM IN DIABETIC PATIENTS Type 1 and Type 2 diabetes affect approximately 34 ¥ a million people in the U.S'. or 10 percent of the U. population. May replace daily burden of blood glucose ‘monitoring and insulin replacement therapy,
Slide 31: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an AAV vector to deliver the Pdx1 and MafAgenes to the pancreas. ‘Transforms alpha cells in the pancreas into POX functional beta-like cells, which can produce insulin oF but are
Slide 32: Key Milestones Through Q1 2022 & Beyond
KEY MILESTONES THROUGH Q11 2022 & BEYOND COMPLET! + Successful completion of technology transferand scale-up ‘of REQORSA, + Inigiated site recruitment for both Acclaim clinica rials + Reported preclinical data for REQORSA in combination with targeted therapies and immunatherapies + Received Centrali
Slide 33: Some Targeted Therapy Company Valuations
SOME TARGETED THERAPY COMPANY VALUATIONS aus compar | sweor | excunce | mocaron lyoQbanaes] russe | vatuanon Helena Headand Nek, Sg IOWA nasdog aves NEGLGCwone UlecelLN-45phase3t) $227 lon locherepet ‘LymphocyticLeukemia at Teropeutes MAT naséog —_NSCLGColorecalReral arcacs savin Phases) ——_—s8.26Bl
Slide 34: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman, President & Chief Executive Officer + 30+ years of expertisein corporate law, including corporate governance, in biotech industry + Former owner of securities broker dealer firm RYAN CONFER, MS. Chief Financial Officer + 10+ years of CLeve
Slide 35: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD HEMANT KUMAR, PHD. Senior Vice President, Intellectual Property Chief Manufacturing & Technology Officer and Licensing + Recognized global expert in Chemistry, Manufacture + 20+ years of expertisein biotech IP law, business evelopment, licensing
Slide 36: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD. JACK A. ROTH MD. FACS, Chairman Professor and Bud Johnson Distinguished Clinical Chair, Department of Thoracicand Cardiovascular Surgery: Chief, Section of Thoracic Molecular Oncology; Professor of Molecular and Cellular Oncology; UT MO Anderson Cancer Center
Slide 37: Clinical Advisory Board
MEET OUR TEAM CLINICAL ADVISORY BOARD. MICHAEL MORSE MD, MHS, FACP. + Professor of Medicine, Division of Medical Oncology inthe Department of Surgery at Duke University Research expertise n targeted therapies and immunotherapies for cancer ANDREW BECKER MD, PHD. President and Founder, Becker Pharmac
Slide 38: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS fi \ RODNEY VARNER, JD + 30+ years of expertisein corporate law, including corporate governance, in botech industry + Former owner of securities broker dealer firm JOSE A. MORENO TOSCANO Board Director Chief Executive Officer, LFB USAIne + 20+ years of experience in
Slide 39: We Believe in a Future of Transformational Patient Care
WE BELIEVE 215" CENTURY GENE THERAPIES LARGE MARKETS AND UNMET NEED IN A FUTURE OF COMBINATION TRIALS WITH TOP TRANSFORMATIONAL SELLING DRUGS TWO FDA FAST TRACK DESIGNATIONS PATIENT CARE EXPLORING NEW INDICATIONS AND PARTNERSHIPS ‘Nasdag:GNPX 39
Slide 40: Genprex Contact
oO Genprex’ NASDAQ: GNPX (877)774-GNPX | investors@genprex.com ‘Nasdaq: GNPK
Slide 41: Appendix
Slide 42: Two New Combination Clinical Trials
TWO NEW COMBINATION CLINICAL TRIALS = KEYTRUDA (ia 458i — (1, (pembrolizumab] a (ONCOPREXE NanoparticleDeliverySystem isthe lipid nanopartice delivery system used in REQORSA™, Nasdag:GNPX
Slide 43: Effects of Genetic Alterations in Suppressor Genes
EFFECTS OF GENETIC ALTERATIONS IN SUPPRESSOR GENES ‘The most common genetic alterations present in NSCLC are located in tumor-suppressor genes against whichno targeted agents have been developed. ‘= Regulation of Malignant Tumor Growth ‘= Insensitivity to Growth-inhibitory Signals = Evasions of Prog
Slide 44: Why Systemic Gene Therapy?
WHY SYSTEMIC GENE THERAPY? Lipid nanoparticles have been shown to encapsulate plasmid DNA, which allows the delivery of gene therapeutic agents intravenously to distant metastases Lipid nanoparticles with TUSC2 have up to a 33-fold affinity for cancer cells compared to healthy cells No need to attac
Slide 45: Why TUSC2?
WHY TUSC2? + 80% of all lung cancer cells lack the TUSC2 tumor suppressor gene + Lossor reduction of TUSC2 expression is associated with significantly worse overall survival + Premalignant lesions express significantly lower levels of TUSC2 compared with normal bronchial epithelia © Genprex ‘Nasdaq:
Slide 46: Viral vs. Non-Viral Vectors
VIRAL VS. NON-VIRAL VECTORS ‘The most common viral vectors are adenoviruses and retroviruses + High level of transfection efficiency = Generally stable + Less specificity of target cells + Can be immunogenic because capsid and viral proteins cause inflammation + Reported cases of death and causing l
Slide 47: Other Potential Cancer Indications
OTHER POTENTIAL CANCER INDICATIONS The region of the TUSC2 tumor suppressor gene is associated with chromosome 3p. In addition to NSCLC, other potential indications include: Thyroid Renal Breast Head & Neck Mesothelioma Ovary
Slide 48: REQORSA + Tagrisso Reduce Tumor Growth
REQORSA + TAGRISSO REDUCE TUMOR GROWTH EFFECT OF TAGRISSO (OSIMERTINIB) + TUSC2 ON A549-LUC METASTASIS ON NSG MICE Perry — (simertinib+TUSC2 on AS49 lung met in NSG mice Week 3 Week 3 *p=0005 v2 Oumar Figure 4A. TUSC2 combination wth Osimertni inhibits tumor growth and signfcanty prolongs survival.)
Slide 49: Effect of REQORSA + Carbo + Keytruda on Humanized Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Carbo+Pembro Effect of Carbo+Pembro+TUSC2 on TUSc2_CarbotPembro_+TUSC2 ‘A549 lung met on Hu-NSG - 4% of change (wk2 vs wk5) tumor intensity Pembrolizumob is the generic nome for Keytrudo. Nasdag:GNEX 49
Slide 50: Effect of REQORSA + Carbo + Keytruda on Humanized Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS 6x10°. 210° otal Flux [pls] 22 33 Pembrolizumob is the generic name for Keytrudo. MODEL Effect of CarbotPembro+TUSC2 on A549 lung met on Hu-NSG No treatment Je TUSC2 410°. Carbo+Pembro J+ Carbo+Pembro+TUSC2 2x10" p14 28 35 = 0.00